Síntese e Caracterização de Novos Complexos de Ru(III) com Ligantes Nitrogenados Heterocíclicos e Potencial Atividade Antitumoral

Abstract

Cancer is a genetic disease caused by mutations in the DNA that can develop in any part of the body. Its treatment follows different approaches, including chemotherapy, which can be quite aggressive. Ruthenium compounds associated with heterocyclic nitrogen ligands have been well studied because of their promising antitumor activity, some of them already present good results and are in the preclinical phase, such as [H-Imidazole] [trans-RuCl4(imidazole)(DMSO)] (NAMI-A) and [H-indazole][trans-RuCl4(indazole)2] (KP1019). In this work, six Ru coordination compounds were synthesized, four of them being unpublished, with heterocyclic nitrogenous ligands 2-(1H-pyrazole)-1-pyridine (L1 ), (1-(pyridine-2)-1H-pyrazole-4-il)methanol (L2 ), ethyl-4-((1-(pyridine-2)-1H-pyrazole-4-il)methyl)pipyrazine-1-carboxylate (L3 ) e 1-(4-((1-(pyridine-2-)-1H-pyrazole-4-)methil)pipyrazine-1-)etanone (L4 ) which are believed to have potential antitumor activity. The compounds were synthesized by reaction under reflux and characterized by: infrared and Uv/Vis spectroscopy, 1H nuclear magnetic resonance spectroscopy, elemental analysis (CHNS), single crystal x-ray diffraction and cyclic voltammetry. The binders used have the same target nucleus for coordination consisting of a pyridine ring and a pyrazole ring. The ligands showed two different modes of coordination to the metal, a bidentate, forming a chelate with the metal, occurs with the ligands L 1 and L 2 and another monodentate, where the ligand coordinates with the metal only by the nitrogen atom of the pyrazole ring, the which occurs with ligands L 3 and L 4 .